🇺🇸 long acting beta agonist in United States
8 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 8
Most-reported reactions
- Chronic Obstructive Pulmonary Disease — 2 reports (25%)
- Diarrhoea — 1 report (12.5%)
- Drug Interaction — 1 report (12.5%)
- Medication Error — 1 report (12.5%)
- Toxicity To Various Agents — 1 report (12.5%)
- Treatment Failure — 1 report (12.5%)
- Ventricular Tachycardia — 1 report (12.5%)
Other Respiratory / Pulmonology approved in United States
Frequently asked questions
Is long acting beta agonist approved in United States?
long acting beta agonist does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for long acting beta agonist in United States?
University of Alberta is the originator. The local marketing authorisation holder may differ — check the official source linked above.